(Circulation. 2001;103:981.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Effects of Endothelin A Receptor Blockade on Endothelial Function in Patients With Chronic Heart Failure
From the Department of Cardiology, University of Vienna, Austria.
Correspondence to Thomas Neunteufl, MD, Department of Cardiology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Email thomas.neunteufl{at}univie.ac.at
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Chronic heart failure (CHF) is associated with impaired endothelium-dependent vasodilation and increased basal vascular tone due, in part, to elevated endothelin-1 plasma levels. In the present study, we investigated whether a reduction of vascular tone using an endothelin A receptor blocker attenuates the impairment of endothelium-dependent, flow-mediated vasodilation (FMD).
Methods and Results—Twenty-one patients with CHF randomly received either the endothelin A receptor blocker LU 135252 (30 mg/d, n=7; 300 mg/d, n=7) or a placebo (n=7). Using high-resolution ultrasound, FMD and endothelium-independent, nitroglycerin-induced dilation of the brachial artery were assessed at baseline in the 21 patients with CHF and in 11 controls and after 3 weeks treatment in the 21 patients with CHF. FMD at baseline was impaired in all 21 patients with CHF (3.2±2%) when compared with the 11 controls (9.7±4.9%; P=0.0005). In comparison with baseline, FMD significantly improved after 3 weeks of treatment with LU 135252 in all 14 patients receiving it (from 3.0±2.0% to 4.9±2.9%; P=0.04), but FMD remained unchanged with placebo. Subgroup analysis, according to different dosages, revealed a significant increase of FMD compared with baseline (from 2.4±1.5% to 5.5±2.4%; P=0.03) in the patients treated with the low-dose (30 mg/d), whereas a high dose of 300 mg/d failed to increase FMD significantly. Improvement in the high-dose group, however, may have been masked by reduced vasodilator capacity due to a significant increase in vessel size (from 4.8±0.4 to 5.1±0.7 mm; P=0.03).
Conclusions—These results suggest that endothelin A receptor blockade improves FMD in CHF patients.
Key Words: heart failure • endothelin • endothelium
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patients with chronic heart failure (CHF) are characterized by increased vasoconstriction and a reduced vasodilatory response to exercise.1 In addition to various systemic mechanisms, including increased sympathetic activation and stimulation of the renin-angiotensin system, there is evidence that the endothelium plays an important role in the regulation of vascular tone.2
With regard to abnormal vasodilator response, previous clinical studies have demonstrated endothelial dysfunction of both large conduit arteries and small resistance arteries in patients with CHF.3 In particular, the role of the endothelium-derived relaxing factor nitric oxide (NO) has received considerable attention. Impaired smooth muscle responsiveness to NO stimulation, impaired L-arginine availability or use, increased NO degradation, reduced NO synthase activity, and endothelial release of vasoconstricting prostanoids have all been implicated in this impaired response.4 5 Moreover, elevated plasma levels of endothelin-1 (ET-1) and its precursor big ET-1 in patients with advanced heart failure6 7 8 suggest that the vasoconstrictor activity of this peptide contributes to the increased basal vascular tone in CHF.9
Because vascular tone is a result of various, simultaneously acting vasodilators and vasoconstrictors,10 11 impaired endothelium-dependent vasodilation may result not only from the reduced effectiveness of the NO system, but also from the increased basal vascular tone counteracting vasodilation. Therefore, an ET receptor antagonist may improve endothelium-dependent flow-mediated vasodilation (FMD) in patients with CHF by reducing increased basal vasoconstriction.
ET-1 exerts a variety of effects via the activation of specific receptors. Type A receptors (ETA) are expressed by vascular smooth muscle cells and cause vasoconstriction.12 Type B receptors (ETB) have dual functions depending on their location: when expressed by vascular smooth muscle cells, they mediate vasoconstriction, but when expressed by endothelial cells, they are linked to vasodilation via NO and/or prostacyclin synthesis.13 14 Because a nonselective ET receptor blocker inhibits both ET-mediated vasoconstriction and vasodilation, selective ETA receptor blockade may be more effective than nonselective blockade in improving endothelium-dependent vasodilation.15
In the present study, we sought to determine the effects of 2 different dosages of LU 135252, a specific ETA receptor antagonist, on the FMD of the brachial artery in patients with advanced heart failure.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Design
LU 135252 (Knoll AG) is an orally active, ETA receptor-selective antagonist that is currently being investigated in a multicenter, prospective, randomized, placebo-controlled dose-finding trial of patients with CHF. A study was designed in patients who were recruited locally at the University of Vienna, Austria, to investigate FMD and nitroglycerin-induced dilation (NMD), as modified by low- and high-dose LU 135252 treatment over a 3-week period. Measurements of endothelial function were performed on all available patients who were randomly assigned to receive placebo (7 patients), 30 mg of LU 135252 per day (7 patients), or 300 mg of LU 135252 per day (7 patients) during the double-blind study period.
Patients
Patients were enrolled in the study if they met the
following criteria: (1) age >18 years; (2) present or recent NYHA
class III heart failure, on the basis of ischemic heart disease or
idiopathic dilated cardiomyopathy; (3) left ventricular ejection
fraction 
35%; (4) pulmonary capillary wedge pressure 
12 mm Hg;
and (5) cardiac index 2.6
L · min–1 · m–2.
The protocol was approved by the institutional ethics committee, and
all patients gave written informed consent before
inclusion.
Twenty-one patients (3 women and 18 men; mean age, 57 years)
with CHF (due to idiopathic dilated cardiomyopathy in 12 patients and
ischemic cardiomyopathy in 9 patients) who had echocardiographic signs
of cardiomegaly (mean left ventricular end-diastolic diameter of 69±9
mm) were studied. All patients were in NYHA functional class III.
Systolic left ventricular dysfunction was documented as an average left
ventricular ejection fraction of 20±6%, which was determined by
radionuclide angiography. Mean pulmonary capillary wedge pressure was
19±5 mm Hg, and mean cardiac index was 2.0±0.3
L · min–1 · m–2,
as assessed by right heart catheterization. Characteristics of patients
with CHF, according to subgroups, are presented in
Table 1
. No differences were found with respect to
age, sex, diagnosis, body mass index, cholesterol levels, distribution
of diabetics or smokers, left ventricular ejection fraction, or left
ventricular end-diastolic diameter.
|
All 21 patients received background heart failure therapy
with digitalis, furosemide, and high-dose ACE-inhibitors. In addition,
11 patients were treated with ß-blockers and 2 patients received
additional angiotensin II receptor blockers, as shown in
Table 2. Patients followed a stable dose of their CHF
therapies (ACE-inhibitors, ß blockers, and angiotensin II receptor
blockers) for at least 3 months before the present study.
|
The CHF patient group included 6 smokers (29%), 6 patients
with diabetes mellitus (29%), and 5 patients with hypercholesterolemia
(24%). The distribution of risk factors according to the underlying
disease was as follows. The patient group with ischemic cardiomyopathy
(n=9) included 2 smokers (22%), 3 patients with diabetes mellitus
(33%), and 1 patient with hypercholesterolemia (11%). Patients with
idiopathic cardiomyopathy (n=12) included 4 smokers (33%), 3 patients
with diabetes mellitus (25%), and 4 patients with hypercholesterolemia
(33%) (Table 3).
|
Controls
Eleven age- and sex-matched subjects without CHF or
coronary artery disease (excluded by angiography) volunteered to be
controls. Because the CHF patients displayed numerous risk factors,
sex- and age-matched controls with several risk factors were included
for adequate comparison.
The demographic and clinical characteristics of the 21 CHF
patients in comparison with the 11 controls are given in
Table 3
. No differences between CHF patients and controls
were observed with regard to body mass index, cholesterol, or
distribution of diabetics or smokers.
Protocols
Baseline FMD and NMD were measured 8 hours after
routine morning medications. On the following day, blood sampling was
performed 2 hours after routine morning medications. The randomized
study drug was then administered and continued for the next 3 weeks.
One day before the end of the study, FMD and NMD measurements were
repeated 8 hours after morning medications, which included the study
drug. The next day, blood sampling was performed 2 hours after morning
medications, which included the study drug.
Assessment of FMD and NMD
Ultrasound measurements were performed according to
the method described by Celermajer et
al16 using high-resolution
ultrasound (Hewlett Packard Sonos 2500) with a 7.5-MHz linear array
transducer. Diameter measurements of the right brachial artery were
taken at rest after supine rest for at least 10 minutes, after cuff
deflation completing suprasystolic compression (240 mm Hg) of the
right upper arm for 4.5 minutes, and after sublingual application of
0.8 mg of nitroglycerin. Scans were taken of the brachial artery
proximal to the bifurcation of the radial and the ulnar artery by the
same ultrasound operator. After optimal transducer positioning, the arm
was kept in the same position and the skin was marked. Lumen diameters
were measured from one media-adventitia interface to the other at least
3 times at baseline, every 20 seconds after reactive hyperemia, and
subsequent to the administration of nitroglycerin. The maximum FMD and
NMD diameters were taken as the average of the 3 consecutive maximum
diameter measurements. Vasodilation was then calculated as the percent
change in diameter over the baseline value.
To verify that suprasystolic compression of the brachial artery produced adequate increases in blood flow, flow velocity was measured at rest and within 15 seconds after cuff deflation. Blood flow was calculated by multiplying the velocity time integral by the heart rate and the vessel cross-sectional area [3.14x(D2/4); D indicates diameter]. Reactive hyperemia was then calculated as the percent change in flow during hyperemia over the baseline value.
Big ET-1
Our assay quantified the sum of big ET-1 and
C-terminal big ET-1 without discrimination between the 2
peptides.17 We evaluated
circulating big ET-1 and the C-terminal fragment on the basis of the
assumption that they may reflect ET overproduction more accurately than
circulating ET-1. The C-terminal fragment of big ET-1 is released
during a proteolytic step to produce ET. Because ET-1, like other
peptides with high biological activity, is rapidly
cleared18 and acts mainly
paracrine,19 the majority of
it may never reach the circulation. However, precursor elements without
biological activity often circulate in higher concentrations, integrate
the secretory activity of endocrine cells, and open an analytic
window.20 In addition, there
is no evidence for an increase in ET-converting enzyme activity in
patients with heart failure compared with normal
patients.21 22
To determine plasma levels of big ET-1, venous blood samples were drawn from an indwelling catheter after at least 30 minutes of rest. Test tubes were placed on ice and centrifuged immediately. Plasma samples were stored at -70°C until they were analyzed. Plasma big ET-1 levels were measured by an extraction-based radioimmune assay (Biomedica). Our reference range is 0.8 to 1.8 fmol/mL.
Statistical Analyses
Results are expressed as mean±SD. The Student’s
test for continuous variables and Fischer’s exact test for categorical
data were used to compare baseline characteristics, vessel size, FMD,
NMD, hyperemia, and big ET-1 levels between groups. Paired
t tests were performed to
estimate the effects of 3 weeks of treatment on vessel size, FMD, NMD,
hyperemia, and big ET-1 levels within the LU 135252 group, the LU
135252 subgroups, and the placebo group. The nonparametric correlation
coefficient (Spearman’s r) was
used to quantify the relationship between the change of vessel size and
NMD by treatment with different doses of LU 135252 or placebo.
Differences were considered significant at
P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Vasodilation and Blood Flow Responses
Vessel size and hyperemia were similar in CHF patients and age- and sex-matched controls. Thus, it can be assumed that the stimulus for FMD was similar in both study groups. However, FMD values were significantly impaired in patients with CHF when compared with controls (9.7±4.9% versus 3.2±2.0%; P=0.0005), whereas NMD values were similar in both groups (Table 3
) and comparable to those reported in patients with
similar vessel sizes and risk factor
profiles.16 23
When comparing all patients receiving LU 135252 with those
taking the placebo, vessel size, hyperemia, FMD, and NMD were not
different between groups at baseline
(Table 4). However, within these 2 groups, a
significant improvement of FMD (from 3.0±2.0% to 4.9±2.9%;
P=0.04) was found after 3 weeks
of ETA receptor blockade but not after placebo
intake
(Figure 1 and
Table 4). NMD, vessel size, and hyperemia remained
unchanged in both the placebo and the LU 135252-treated groups
(Table 4).
|
|
The analyses of subgroups with regard to different dosages
are as follows. In patients treated with a low dose of LU 135252 (30
mg/d), no changes were found with respect to vessel diameter at rest or
hyperemia. FMD increased from 2.4±1.5% to 5.5±2.4%
(P=0.03), but NMD remained
unchanged
(Figure 2 and
Table 4). In contrast, a daily dose of 300 mg of LU
135252 resulted in a significant increase in the vessel size of the
brachial artery (from 4.8±0.4 to 5.1±0.7 mm;
P=0.03). However, FMD did not
change in this group. This was likely due to the significant increase
in baseline diameter. Remarkably though, NMD was significantly reduced
(from 13.5±9.0% to 7.1±6.8%;
P=0.04).
|
Linear regression analysis revealed close negative
correlations between vessel diameter and NMD over the 3 weeks of
treatment (r=-0.81,
P=0.0001)
(Figure 2
and Table 4).
No difference could be observed when comparing vessel size
(5.0±0.6 versus 5.1±0.6 mm), FMD (3.4±1.7% versus 2.4±1.7%), and
NMD (12.1±5.2% versus 10.4±6.7%) in patients with idiopathic (n=12)
versus ischemic (n=9) cardiomyopathy. In the group with 30 mg/d LU
135252, FMD increased in 2 of 2 patients with ischemic cardiomyopathy
and in 3 of 5 patients with idiopathic cardiomyopathy. In the group
receiving 300 mg/d LU 135252, FMD increased in 2 of 4 patients with
ischemic cardiomyopathy and in 1 of 3 patients with idiopathic
cardiomyopathy
(Figure 2).
There was no significant difference in vessel size (5.1±0.6 versus 5.0±0.5 mm), FMD (2.2±1.6% versus 3.7±1.7%), or NMD (9.1±5.6% versus 13.3±5.5%) between patients with (n=11) versus without (n=10) ß-blocker therapy.
Big ET-1 Plasma Levels
The mean big ET-1 plasma concentration in the CHF
patients was 5.0±2.4 fmol/mL. This was markedly higher than the cut
point of 4.3 fmol/mL, indicating a very poor short-term
prognosis.8 24 In
contrast, the controls had a significantly lower big ET-1 plasma
concentration compared with the CHF patients (2.3±0.7 fmol/mL versus
5.0±2.4 fmol/mL; P=0.0005)
(Table 3). Three weeks of treatment with LU 135252 (or
placebo) had no influence on the elevated big ET-1 plasma levels
(Table 4).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study demonstrates that the ETA receptor antagonist LU 135252 has the potential to attenuate the impairment of FMD in patients with CHF. An improvement in the FMD of the brachial artery after 3 weeks of treatment was observed specifically in patients treated with 30 mg of LU 135252 per day; 300 mg/d did not influence endothelium-dependent vasodilation. In contrast, brachial artery diameter remained unaffected by the low-dose treatment but increased significantly with the higher dose.
Physiologically, ET-1 may interact with short-acting regulatory systems such as NO, thereby maintaining vascular tone and simultaneously allowing flexibility of the vascular tone on demand.10 In addition to myogenically or neurogenically induced contraction,10 ET-1 is responsible for basal vasoconstrictive tone.25 NO, however, mediates the vasodilation of peripheral conduit arteries due to an increase in blood flow.26
CHF patients are characterized by impaired endothelium-dependent vasodilation.3 27 Moreover, plasma concentrations of ET-1 and its precursor big ET-1 are elevated in patients with CHF, and ET-1 contributes to increased basal vasomotor tone.6 7 8 Thus, CHF patients in this study were characterized by both impairment of FMD and highly elevated big ET-1 plasma levels. The major hypothesis for improvement of the endothelial function in CHF patients with ET receptor blockers is a reversal of the imbalance between basal vasoconstrictive and vasodilating forces on demand by reducing the increased basal tone.
Recently, Krum and colleagues28 29 observed a reduction in absolute forearm blood flow responses to peak reactive hyperemia, as well as in metabolic vasodilatation during exercise in healthy humans exposed to ET-1 infusion, although basal and stimulated NO production remained unchanged. Thus, it may be suggested that an imbalance of the endothelial regulatory system by increased ET-1 plasma concentrations contributes to the impairment of vasodilator response to shear stress. Furthermore, in an animal model characterized by increased vascular ET-1 generation (spontaneously hypertensive rats), an improvement of FMD and acetylcholine-induced vasodilation was documented after long-term ETA receptor blockade.15 30 The results of the present study in humans with CHF are in accordance with the concept that impaired FMD, accompanied by increased ET-1 production, can be improved by ETA receptor blockade.
ETB receptors expressed by endothelial cells mediate vasorelaxation due to the release of NO or prostacyclin.13 14 Thus, an improvement of FMD in this study may have been partly due to selective ETA receptor blockade, thus focusing the effects of flow-induced ET release on ETB receptors. Previously, it has been shown that increased ET-1 reduces metabolic vasodilation in normal individuals through mechanisms presumably unrelated to altered NO production.29 In our study, however, the inability of ET-1 to increase endothelial NO production may have been abrogated by specific ETA receptor blockade.31 Moreover, although the pressor effect of ET-1 does not seem to be modified by cyclooxygenase inhibition, vasoconstrictor prostanoids (thromboxane) seem to potentiate the regional vasoconstriction induced by ET-1.32 In view of the fact that long-term ETA receptor blockade increases the participation of cyclooxygenase products in the FMD of animals,15 we think it is possible that LU 135252 in our patients may have prevented the vasoconstrictor prostanoid-dependent activity and thus favored the effect of vasodilator prostanoids on flow stimulation.
The lack of improvement in FMD with a high dose of LU 135252 seems to be a limitation of this study. However, an improvement in FMD with higher doses of LU 135252 could have been masked by vasodilation, because an increase in vessel size caused by ETA receptor blockade is closely related to reduced vasodilator capacity. FMD was preserved even under high-dose treatment, whereas NMD was substantially blunted. Moreover, our results are in accordance with previous studies, indicating an inverse correlation between vessel size and vasodilation after hyperemia and nitroglycerin, respectively.16 23
In vitro experiments have demonstrated that LU 135252
has a 100-fold higher affinity to human ETA
than to human ETB receptors (A.G. Knoll and L.
Unger, unpublished data, 2000). Despite the preserved
selectivity of ETA receptor blockade at higher
doses of LU 135252 in rats (29
mg · kg–1 · d–1
equals 2100 mg/d for a human weighing 70
kg),33 these results cannot
be directly transferred to humans. Theoretically, it is possible that
LU 135252 is a selective blocker of ETA
receptors at a lower dose (30 mg/d) but that at higher dosage (300
mg/d), it also blocks ETB receptors. Therefore,
it might be possible that the higher concentration of the
ETA receptor blocker inhibits, at least in part,
NO production and thus shows little effect on FMD.
In conclusion, this study indicates that the ETA receptor blocker LU 135252 attenuates the impairment of FMD seen in patients with CHF. Our findings support the concept that endothelial dysfunction in CHF is caused by an imbalance between the increased, continuously acting vasoconstrictor ET-1 and short-acting regulatory systems like NO.
|
Footnotes |
|---|
Guest Editor for this article was Suzanne Oparil, MD, University of Alabama at Birmingham.
Received August 2, 2000; revision received October 13, 2000; accepted October 16, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Zelis R, Mason DT, Braunwald E. A comparison on the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest. 1968;47:960–997.
2.
Henderson AH.
Endothelium in control (St Cyres lecture).
Br Heart J. 1991;65:116–125.
3. Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596–1601.[Medline] [Order article via Infotrieve]
4. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51–60.[Medline] [Order article via Infotrieve]
5. Kiowski W, Sütsch G, Schalcher CH, et al. Endothelial control of vascular tone in chronic heart failure. J Cardiovasc Pharmacol. 1998;32:67–73.
6.
Cody RJ, Haas GJ,
Binkley PF, et al. Plasma endothelin correlates with the extent of
pulmonary hypertension in patients with chronic congestive heart
failure. Circulation. 1992;85:504–509.
7. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732–736.[Medline] [Order article via Infotrieve]
8. Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633–641.[Abstract]
9.
Love MP, Haynes WG,
Gray GA, et al. Vasodilator effects of endothelin-converting enzyme
inhibition and endothelin ETA receptor blockade in chronic heart
failure patients treated with ACE inhibitors.
Circulation. 1996;94:2131–2137.
10. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol. 1999;31:5–14.[Medline] [Order article via Infotrieve]
11. Gray GG, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther. 1996;72:109–148.[Medline] [Order article via Infotrieve]
12. Riezebos J, Watts IS, Vallance PJ. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol. 1994;111:609–615.[Medline] [Order article via Infotrieve]
13. Takayanagi R, Kitazumi K, Takasaki C, et al. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett. 1991;282:103–106.[Medline] [Order article via Infotrieve]
14. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 1993;91:1367–1373.
15.
Iglarz M,
Matrougui K, Lévy B, et al. Chronic blockade of endothelin
ETA receptors improves flow dependent dilation
in resistance arteries of hypertensive rats.
Cardiovasc Res. 1998;39:657–664.
16. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115.[Medline] [Order article via Infotrieve]
17. Schuller M, Stetter R, Skrabal S, et al. Radioimmunoassay of immunoreactive C-terminal big-endothelin (22–38). Eur J Clin Chem Clin Biochem. 1991;29:147–150.[Medline] [Order article via Infotrieve]
18. Weitzberg E, Ahlborg G, Lundberg JM. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun. 1991;180:1298–1303.[Medline] [Order article via Infotrieve]
19.
Wagner OF, Christ
G, Wojta T. Polar secretion of endothelin-1 by cultured endothelial
cells. J Biol Chem. 1992;267:16066–16068.
20. Hall C, Kjekshus J, Eneroth P, et al. The plasma concentration of N-terminal proatrial natriuretic factor ANF (1–98) is related to prognosis in severe heart failure. Clin Cardiol. 1994;17:191–195.[Medline] [Order article via Infotrieve]
21. Kobayashi T, Miyauchi T, Sakai S, et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol. 1999;276(4 Pt 2):H1197–H1206.
22.
Zolk O, Quattek
J, Sitzler G, et al. Expression of endothelin-1, endothelin-converting
enzyme, and endothelin receptors in chronic heart failure.
Circulation. 1999;99:2118–2123.
23. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 1997;129:111–118.[Medline] [Order article via Infotrieve]
24.
Hülsmann M,
Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and
big endothelin plasma levels to predict short-term prognosis of
patients with chronic heart failure.
J Am Coll Cardiol. 1998;32:1695–1700.
25. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852–854.[Medline] [Order article via Infotrieve]
26.
Joannides R,
Haefeli WE, Linder L, et al. Nitric oxide is responsible for
flow-dependent dilation of human peripheral conduit arteries in vivo.
Circulation. 1995;91:1314–1319.
27.
Drexler H, Zeiher
AH, Wollschläger H, et al. Flow-dependent artery dilation in humans.
Circulation. 1989;80:466–474.
28. Krum H, Katz SD. Effect of endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with heart failure. Am J Cardiol. 1998;81:355–358.[Medline] [Order article via Infotrieve]
29. Krum H, Cranswick N, Pellizzer AM. Effect of endothelin-1 on endothelium-derived vascular responsiveness in man. Clin Sci. 1998;95:151–155.[Medline] [Order article via Infotrieve]
30. Miyamori I, Takeda Y, Yoneda T, et al. Endothelin release from mesenteric arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1991;17:408–410.
31. Mickley EJ, Gray GA, Webb DJ. Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol. 1997;120:1376–1382.[Medline] [Order article via Infotrieve]
32. Gardiner SM, Compton AM, Bennett T. Effect of indomethacin on the regional haemodynamic responses to low doses of endothelins and sarafotoxin. Br J Pharmacol. 1990;100:158–162.[Medline] [Order article via Infotrieve]
33.
Mulder P, Richard
V, Bouchart F, et al. Selective ETA receptor
blockade prevents left ventricular remodeling and deterioration of
cardiac function in experimental heart failure.
Cardiovasc Res. 1998;39:600–608.
This article has been cited by other articles:
 |
|
 |
|
  M. Kooijman, D. H. J. Thijssen, P. C. E. de Groot, M. W. P. Bleeker, H. J. M. van Kuppevelt, D. J. Green, G. A. Rongen, P. Smits, and M. T. E. Hopman Flow-mediated dilatation in the superficial femoral artery is nitric oxide mediated in humans J. Physiol., February 15, 2008; 586(4): 1137 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Parker, S. J. Ridout, and D. N. Proctor Age and flow-mediated dilation: a comparison of dilatory responsiveness in the brachial and popliteal arteries Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3043 - H3049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E Pyke and M. E Tschakovsky The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function J. Physiol., October 15, 2005; 568(2): 357 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Meyer, D. Mortl, K. Strecker, M. Hulsmann, V. Kulemann, T. Neunteufl, R. Pacher, and R. Berger Flow-Mediated Vasodilation Predicts Outcome in Patients With Chronic Heart Failure: Comparison With B-Type Natriuretic Peptide J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1011 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Tschakovsky and K. E. Pyke Counterpoint: Flow-mediated dilation does not reflect nitric oxide-mediated endothelial function J Appl Physiol, September 1, 2005; 99(3): 1235 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gomez-Cerezo, J. J. Rios Blanco, I. Suarez Garcia, P. Moreno Anaya, P. Garcia Raya, E. Vazquez-Munoz, and F. J. Barbado Hernandez Noninvasive Study of Endothelial Function in White Coat Hypertension Hypertension, September 1, 2002; 40(3): 304 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V Agapitov and W. G Haynes Role of endothelin in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 1 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Cardillo, U. Campia, C. M. Kilcoyne, M. B. Bryant, and J. A. Panza Improved Endothelium-Dependent Vasodilation After Blockade of Endothelin Receptors in Patients With Essential Hypertension Circulation, January 29, 2002; 105(4): 452 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng Endothelin Receptor Blockade in Congestive Heart Failure Circulation, October 30, 2001; 104 (18): e96 - e96. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||